PFO
ALLO icon

Pathstone Family Office’s Allogene Therapeutics ALLO Stock Holding History

Pathstone Family Office’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-231
Closed -$10K – 792
2020
Q2 		$10K Buy
+231
New +$8.35K ﹤0.01% 510
2019
Q3 		– Sell
-27,250
Closed -$732K – 612
2019
Q2 		$732K Buy
+27,250
New +$759K 0.09% 102
2019
Q1 		– Sell
-26,500
Closed -$713K – 883
2018
Q4 		$713K Buy
+26,500
New +$704K 0.2% 43

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Pathstone Family Office's ALLO Position: Q3 2020 in Review

Pathstone Family Office sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 231 shares — an estimated $10K sold.

Pathstone Family Office first reported a position in ALLO in Q4 2018 and held it in 3 quarters. The position peaked at $732K in Q2 2019. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Pathstone Family Office reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 231 Allogene Therapeutics shares in Q3 2020, an estimated $10K.
  • Pathstone Family Office first reported a position in Allogene Therapeutics in Q4 2018 and held it in 3 quarters.
  • Pathstone Family Office's Allogene Therapeutics position peaked at $732K in Q2 2019.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.